Cadrenal Therapeutics, Inc. (CVKD) is valued at $30.00/share based on probability adjusted DCF model, accounting for potential future revenues for tecarfarin in various conditions. The model hinges on tecarfarin’s clinical success, subject to adjustment based on future results. The company recently acquired Factor XIa inhibitors from eXIthera Pharmaceuticals, including frunexian and EP-7327, for anticoagulant therapy development. Frunexian, a small-molecule inhibitor of Factor XIa, showed promising results in Phase 1 trials and is planned for further clinical trials. Cadrenal plans to conduct a Phase 2 trial for tecarfarin in ESKD patients transitioning to dialysis, addressing the need for effective anticoagulant therapy in this population. The company’s financial update for Q2 2025 showed R&D expenses of $1.1 million and G&A expenses of $2.7 million, with approximately $5.6 million in cash and cash equivalents. Cadrenal plans to raise additional capital for upcoming clinical trials. The acquisition of frunexian and focus on ESKD patients for tecarfarin development show promise for positive results that may de-risk its development in other indications, maintaining a valuation of $30 per share.

Read more at Yahoo Finance: Cadrenal Therapeutics, Inc.